SCHEMBL2190107

SCHEMBL2190107

CC(C)([C@@H]1CCN(c2ccc(C(F)(F)F)nn2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 4/20 0.47
CYP3A4 P08684 3/20 0.47
NR1I2 O75469 1/20 0.46
THRB P10828 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
POLB P06746 1/20 0.36
CXCR3 P49682 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2188386 1.00 CACNA1B (0.47) CACNA1BCYP3A4NR1I2THRBLMNA
SCHEMBL2190115 0.88 CACNA1B (0.47) CACNA1BCYP3A4NR1I2KDM4EPOLB
SCHEMBL7920460 0.86 CYP3A4 (0.46) CACNA1BCYP3A4NR1I2LMNAMAPT
SCHEMBL2196073 0.86 CYP3A4 (0.46) CACNA1BCYP3A4NR1I2LMNAMAPT
SCHEMBL2189730 0.86 CYP3A4 (0.46) CACNA1BCYP3A4NR1I2LMNAMAPT
SCHEMBL2191575 0.86 CACNA1B (0.51) CACNA1BCYP3A4NR1I2KDM4E
SCHEMBL2188044 0.86 CACNA1B (0.51) CACNA1BCYP3A4NR1I2KDM4E
SCHEMBL2191324 0.86 CYP3A4 (0.45) CACNA1BCYP3A4NR1I2KDM4ECA12
SCHEMBL2189267 0.86 CYP3A4 (0.45) CACNA1BCYP3A4NR1I2KDM4ECA12
SCHEMBL2191587 0.85 CACNA1B (0.47) CACNA1BCYP3A4NR1I2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.